Key Adverse Events Following Childhood Cancer
S
Sandeep Batra, MD
Primary Investigator
Overview
The goal of this study is to identify subjects who are more likely to develop a late-occurring complication(s) after undergoing treatment for childhood cancer.
Description
The purpose of this study is to identify key adverse events developing in patients (cases) with a primary cancer diagnosed at age 21 or younger.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
childhood cancer
-
Age: - 21 Years
-
Gender: All
Inclusion Criteria
Diagnosis of primary cancer at age 21 or younger
In active follow-up by a Children's Oncology Group (COG) institution
Development of one of the following key adverse events after initiation of prior cancer therapy:Cardiac dysfunction, Myocardial infarction, Ischemic stroke, Avascular necrosis, Subsequent malignant neoplasm
Exclusion Criteria
Prior allogeneic (non-autologous) hematopoietic cell transplant
Additional Information:Diagnosis of primary cancer at age 21 or younger
In active follow-up by a Children's Oncology Group (COG) institution
Development of one of the following key adverse events after initiation of prior cancer therapy:Cardiac dysfunction, Myocardial infarction, Ischemic stroke, Avascular necrosis, Subsequent malignant neoplasm
Exclusion Criteria
Prior allogeneic (non-autologous) hematopoietic cell transplant
Participants will not be paid for their participation.
Updated on
18 Apr 2024.
Study ID: 1011003233 (PHO-COG-FALLON-ALTE03N1)
Connect with a study center near you
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact